US Patent
US7772243 — 4-phenylamino-quinazolin-6-yl-amides
Composition of Matter · Assigned to Warner Lambert Co LLC · Expires 2032-09-27 · 6y remaining
Vulnerability score
4/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a class of quinazoline compounds with specific chemical structures, including those used in the drug Vizimpro.
USPTO Abstract
This invention provides quinazoline compounds of the formula: wherein: R 1 is halo; R 2 is H or halo; R 3 is a) C 1 -C 3 alkyl, optionally substituted by halo; or b) â(CH 2 ) n -morpholino, â(CH 2 ) n -piperidine, â(CH 2 ) n -piperazine, â(CH 2 ) n â-piperazine-N(C 1 -C 3 alkyl), â(CH 2 ) n -pyrrolidine, or â(CH 2 ) n -imidazole; n is 1 to 4; R 4 is â(CH 2 ) m -Het; Het is morpholine, piperidine, piperazine, piperazine-N(C 1 -C 3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH 2 , NH(C 1 -C 3 alkyl) or N (C 1 -C 3 alkyl) 2 ; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
Drugs covered by this patent
- Vizimpro (Dacomitinib) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.